Profile data is unavailable for this security.
About the company
MediciNova, Inc. is a biopharmaceutical company that is developing therapeutics with a primary focus on neurology, respiratory and liver diseases. The Company's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.
- Revenue in USD (TTM)257.92k
- Net income in USD-12.01m
- Incorporated2000
- Employees13.00
- LocationMediciNova Inc4275 Executive Square, Suite 300LA JOLLA 92037United StatesUSA
- Phone+1 (858) 373-1500
- Fax+1 (858) 404-0048
- Websitehttps://medicinova.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gain Therapeutics Inc | 0.00 | -19.39m | 66.54m | 23.00 | -- | 10.53 | -- | -- | -0.6364 | -0.6364 | 0.00 | 0.1643 | 0.00 | -- | -- | 0.00 | -153.07 | -79.58 | -234.03 | -95.32 | -- | -- | -- | -19,975.78 | -- | -33.79 | 0.067 | -- | -100.00 | -- | 8.34 | -- | 10.39 | -- |
| Coeptis Therapeutics Holdings Inc | 500.99k | -11.28m | 68.11m | 5.00 | -- | 5.88 | -- | 135.95 | -3.47 | -3.47 | 0.1476 | 2.01 | 0.0433 | -- | 11.65 | 100,198.00 | -118.13 | -42.24 | -167.86 | -44.32 | 72.96 | -- | -2,727.81 | -- | -- | -73.66 | 0.0224 | -- | -- | -- | 53.85 | -- | -- | -- |
| XBiotech Inc | 0.00 | -29.16m | 72.26m | 88.00 | -- | 0.4325 | -- | -- | -0.9566 | -0.9566 | 0.00 | 5.48 | 0.00 | -- | -- | 0.00 | -15.25 | -7.74 | -16.08 | -8.02 | -- | -- | -- | -187.68 | -- | -- | 0.00 | -- | -- | -- | -56.90 | -- | 44.92 | -- |
| Nuo Therapeutics Inc | 2.61m | -2.43m | 72.42m | -- | -- | -- | -- | 27.73 | -0.0517 | -0.0517 | 0.0555 | -0.0088 | 1.43 | 4.19 | 5.32 | -- | -133.29 | -121.45 | -289.99 | -243.05 | 70.38 | 78.52 | -93.06 | -424.19 | 1.00 | -17,110.33 | -- | -- | 124.34 | 56.34 | 26.73 | -- | -- | -- |
| Ibio Inc | 500.00k | -20.11m | 72.89m | 20.00 | -- | 0.7626 | -- | 145.77 | -1.44 | -1.44 | 0.0232 | 2.77 | 0.0113 | -- | 15.38 | 25,000.00 | -45.35 | -30.90 | -50.81 | -37.76 | -- | -- | -4,021.60 | -2,374.12 | -- | -- | 0.0127 | -- | 77.78 | -24.57 | -19.00 | -- | -57.50 | -- |
| Maia Biotechnology Inc | 0.00 | -22.34m | 72.95m | 13.00 | -- | 1,628.72 | -- | -- | -0.7504 | -0.7504 | 0.00 | 0.0012 | 0.00 | -- | -- | 0.00 | -212.50 | -208.29 | -602.02 | -373.18 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -17.61 | -- | -- | -- |
| Seres Therapeutics Inc | 351.00k | 5.39m | 74.36m | 103.00 | 13.95 | 1.65 | 7.70 | 211.86 | 0.5892 | 0.5892 | 0.0404 | 4.99 | 0.0022 | -- | -- | 3,407.77 | 3.35 | -42.44 | 4.59 | -55.22 | -- | -- | 1,536.75 | -367.23 | -- | -- | 0.00 | -- | -- | -- | 33.85 | -- | -17.63 | -- |
| ImageneBio Inc | 0.00 | -46.14m | 76.59m | 15.00 | -- | 0.5478 | -- | -- | -8.11 | -8.11 | 0.00 | 12.51 | 0.00 | -- | -- | 0.00 | -29.23 | -29.58 | -31.29 | -33.67 | -- | -- | -- | -407.25 | -- | -- | 0.00 | -- | -100.00 | -- | 27.77 | -- | -- | -- |
| Medicinova Inc | 257.92k | -12.01m | 76.67m | 13.00 | -- | 1.74 | -- | 297.26 | -0.2449 | -0.2449 | 0.0053 | 0.8964 | 0.0049 | -- | -- | 19,840.00 | -22.73 | -15.56 | -24.08 | -16.17 | -- | -- | -4,656.61 | -1,144.98 | -- | -- | 0.00 | -- | -100.00 | -- | -28.91 | -- | -39.68 | -- |
| Tenax Therapeutics Inc | 0.00 | -43.33m | 80.67m | 4.00 | -- | 0.7933 | -- | -- | -1.13 | -1.13 | 0.00 | 16.29 | 0.00 | -- | -- | 0.00 | -42.77 | -99.65 | -44.80 | -118.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -128.28 | -- | -- | -- |
| Champions Oncology Inc | 58.42m | 2.49m | 82.62m | 213.00 | 35.70 | 19.81 | 20.78 | 1.41 | 0.1667 | 0.1667 | 4.14 | 0.3003 | 2.11 | -- | 5.31 | 274,291.10 | 8.78 | -4.67 | 33.91 | -11.66 | 50.11 | 47.28 | 4.16 | -2.79 | -- | -- | 0.0327 | -- | 13.54 | 12.13 | 164.61 | -- | -29.41 | -- |
| eXoZymes Inc | 0.00 | -8.34m | 84.00m | 31.00 | -- | 15.61 | -- | -- | -1.76 | -1.76 | 0.00 | 0.6408 | 0.00 | -- | -- | 0.00 | -147.87 | -- | -393.50 | -- | -- | -- | -- | -- | -- | -- | 0.0217 | -- | -- | -- | -187.55 | -- | -- | -- |
| Pyxis Oncology Inc | 2.82m | -97.09m | 84.06m | 44.00 | -- | 1.22 | -- | 29.81 | -1.58 | -1.58 | 0.0457 | 1.11 | 0.0187 | -- | -- | 64,090.91 | -64.53 | -47.22 | -74.33 | -53.45 | 0.00 | -- | -3,442.77 | -2,233.63 | -- | -- | 0.0006 | -- | -- | -- | -4.80 | -- | -- | -- |
| TuHURA Biosciences Inc | 0.00 | -43.77m | 84.40m | 19.00 | -- | 4.32 | -- | -- | -1.60 | -1.60 | 0.00 | 0.3273 | 0.00 | -- | -- | 0.00 | -286.97 | -- | -456.76 | -- | -- | -- | -- | -- | -- | -9.01 | 0.0286 | -- | -- | -- | -- | -- | -- | -- |
| aTyr Pharma Inc | 190.00k | -75.12m | 87.30m | 56.00 | -- | 1.09 | -- | 459.45 | -0.8345 | -0.8345 | 0.0021 | 0.8188 | 0.0019 | -- | 0.1323 | 3,392.86 | -75.78 | -47.98 | -88.99 | -54.91 | -- | -- | -39,540.53 | -978.90 | -- | -- | 0.0127 | -- | -33.43 | -11.05 | -27.06 | -- | -3.83 | -- |
Data as of Feb 13 2026. Currency figures normalised to MediciNova Inc's reporting currency: US Dollar USD
17.77%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| 3D Investment Partners Pte. Ltd.as of 21 Apr 2025 | 5.50m | 11.20% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 689.83k | 1.40% |
| Citigroup Global Markets, Inc. (Investment Management)as of 30 Sep 2025 | 594.06k | 1.21% |
| Geode Capital Management LLCas of 30 Sep 2025 | 529.70k | 1.08% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 474.75k | 0.97% |
| UBS Securities LLCas of 31 Dec 2025 | 225.66k | 0.46% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 215.28k | 0.44% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 192.50k | 0.39% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 174.60k | 0.36% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2025 | 134.74k | 0.27% |
More ▼
Data from 30 Sep 2025 - 28 Jan 2026Source: FactSet Research Systems Inc.
